AU2011345312A1 - BIN1 expression as a marker of skeletal muscle mass and neurological conditions - Google Patents

BIN1 expression as a marker of skeletal muscle mass and neurological conditions Download PDF

Info

Publication number
AU2011345312A1
AU2011345312A1 AU2011345312A AU2011345312A AU2011345312A1 AU 2011345312 A1 AU2011345312 A1 AU 2011345312A1 AU 2011345312 A AU2011345312 A AU 2011345312A AU 2011345312 A AU2011345312 A AU 2011345312A AU 2011345312 A1 AU2011345312 A1 AU 2011345312A1
Authority
AU
Australia
Prior art keywords
seq
subject
bini
antibody
level
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2011345312A
Other languages
English (en)
Inventor
Darryl Steven SHAW
Neil Gavin SHAW
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SARCOTEIN DIAGNOSTICS LLC
Original Assignee
SARCOTEIN DIAGNOSTICS LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SARCOTEIN DIAGNOSTICS LLC filed Critical SARCOTEIN DIAGNOSTICS LLC
Publication of AU2011345312A1 publication Critical patent/AU2011345312A1/en
Priority to AU2017201661A priority Critical patent/AU2017201661B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6887—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids from muscle, cartilage or connective tissue
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
AU2011345312A 2010-11-09 2011-11-07 BIN1 expression as a marker of skeletal muscle mass and neurological conditions Abandoned AU2011345312A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017201661A AU2017201661B2 (en) 2010-11-09 2017-03-10 BIN1 expression as a marker of skeletal muscle mass and neurological conditions

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41168310P 2010-11-09 2010-11-09
US61/411,683 2010-11-09
PCT/US2011/059574 WO2012087437A2 (en) 2010-11-09 2011-11-07 Bin1 expression as a marker of skeletal muscle mass and neurological conditions

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017201661A Division AU2017201661B2 (en) 2010-11-09 2017-03-10 BIN1 expression as a marker of skeletal muscle mass and neurological conditions

Publications (1)

Publication Number Publication Date
AU2011345312A1 true AU2011345312A1 (en) 2013-06-20

Family

ID=46314702

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2011345312A Abandoned AU2011345312A1 (en) 2010-11-09 2011-11-07 BIN1 expression as a marker of skeletal muscle mass and neurological conditions
AU2017201661A Active AU2017201661B2 (en) 2010-11-09 2017-03-10 BIN1 expression as a marker of skeletal muscle mass and neurological conditions

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017201661A Active AU2017201661B2 (en) 2010-11-09 2017-03-10 BIN1 expression as a marker of skeletal muscle mass and neurological conditions

Country Status (6)

Country Link
US (1) US9891232B2 (https=)
EP (1) EP2638403B1 (https=)
JP (1) JP5866126B2 (https=)
AU (2) AU2011345312A1 (https=)
CA (1) CA2817519C (https=)
WO (1) WO2012087437A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010124240A2 (en) 2009-04-24 2010-10-28 The Regents Of The University Of California Bin1 as a prognostic marker in cardiovascular disease
US8999659B2 (en) 2010-10-20 2015-04-07 The Regents Of The University Of California Body fluid BIN1 as a marker of cardiac health
US9846159B2 (en) 2011-09-30 2017-12-19 Sarcotein Diagnostics, Llc BIN1 expression as a marker of cancer
WO2016141088A1 (en) 2015-03-02 2016-09-09 Sarcotein Diagnostics, Llc 13+/17+ bin1 expression as a marker of cardiac disorders
JP6539511B2 (ja) * 2015-06-17 2019-07-03 花王株式会社 運動機能の判定用マーカー
JP6886241B2 (ja) * 2016-01-07 2021-06-16 味の素株式会社 骨格筋面積の評価方法
MY198194A (en) * 2016-05-02 2023-08-09 Prothena Biosciences Ltd Antibodies Recognizing Tau
US12054543B2 (en) 2018-07-25 2024-08-06 Accurus Biosciences, Inc. CLDN 18.2-specific monoclonal antibodies and methods of use thereof
CA3115077A1 (en) * 2018-10-09 2020-04-16 Ibex Biosciences, Llc Antibodies directed to filamin-a and therapeutic uses thereof
WO2022132859A1 (en) * 2020-12-15 2022-06-23 Arizona Board Of Regents On Behalf Of Arizona State University Antibodies specific for qsox1 and methods of using the same
CN112778414B (zh) * 2020-12-31 2022-04-15 中南大学湘雅二医院 cBIN1抗体及其应用
CN112794900B (zh) * 2020-12-31 2022-10-25 中南大学湘雅二医院 cBIN1抗体及其应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6048702A (en) * 1995-05-05 2000-04-11 The Wistar Institute Of Anatomy And Biology Murine and human box-dependent myc-interacting protein (Bin1) and uses therefor
WO2001004354A2 (en) 1999-07-07 2001-01-18 Regeneron Pharmaceuticals, Inc. Use of ras inhibitors of inhibiting muscle atrophy
US6831063B1 (en) * 1999-08-31 2004-12-14 The Wistar Institute Of Anatomy And Biology Bridging Integrator-2(Bin2) nucleic acid molecules and proteins and uses therefor
US20090088482A1 (en) * 2003-10-14 2009-04-02 The Trustees Of Columbia University In The City New York Compositions and Methods For Treating Heart Failure
ES2367311T3 (es) * 2004-04-15 2011-11-02 University Of Florida Research Foundation, Inc. Productos de degradación proteolítica de map-2 como biomarcadores de diagnóstico para las lesiones neurales.
WO2006009629A2 (en) * 2004-06-10 2006-01-26 New York University Methods and agents for maintaining muscle mass and for preventing muscle atrophy and biomarkers for monitoring same
US20100086481A1 (en) 2006-07-11 2010-04-08 Baird Alison E Differential expression of molecules associated with intra-cerebral hemorrhage
WO2010124240A2 (en) 2009-04-24 2010-10-28 The Regents Of The University Of California Bin1 as a prognostic marker in cardiovascular disease
US8999659B2 (en) * 2010-10-20 2015-04-07 The Regents Of The University Of California Body fluid BIN1 as a marker of cardiac health

Also Published As

Publication number Publication date
CA2817519A1 (en) 2012-06-28
JP2014500960A (ja) 2014-01-16
US20130324432A1 (en) 2013-12-05
WO2012087437A2 (en) 2012-06-28
US9891232B2 (en) 2018-02-13
EP2638403A2 (en) 2013-09-18
EP2638403B1 (en) 2017-03-22
AU2017201661A1 (en) 2017-03-30
AU2017201661B2 (en) 2019-01-17
EP2638403A4 (en) 2014-05-07
WO2012087437A3 (en) 2012-08-16
JP5866126B2 (ja) 2016-02-17
CA2817519C (en) 2020-01-14

Similar Documents

Publication Publication Date Title
AU2017201661B2 (en) BIN1 expression as a marker of skeletal muscle mass and neurological conditions
US20240426842A1 (en) Novel biomarkers and methods for diagnosing and evaluating traumatic brain injury
KR20110020853A (ko) 유전자 또는 단백질 발현 프로파일을 이용한 신장 동종이식 거부반응 진단방법
JP5868409B2 (ja) モエシン断片およびその使用
EP2300624B1 (en) Biomarkers for painful intervertebral discs and methods of use thereof
JP2008532489A (ja) 軽度の変形性関節症のバイオマーカーおよびその使用
US20080107600A1 (en) Gene Marker And Composition For Diagnosis And Treatment Of Neurological Disorders And Diseases And Use Of The Same
US7709215B2 (en) Method for diagnosing and treating acute joint injury
WO2008079406A2 (en) Gene expression markers for inflammatory bowel disease
KR101289134B1 (ko) 유전성 샤르코-마리-투스 말초신경병증의 cmt4b3 아형에 대한 원인 유전자로서의 sbf1(mtmr5) 돌연변이 유전자 및 이를 이용한 상기 질병의 진단방법 및 진단용 조성물
JP2013039111A (ja) スプライシングバリアント
JP2007524408A (ja) 精神障害の診断および処置
US20100022404A1 (en) Gene/protein marker for prediction or diagnosis of pharmacological efficacy of aurora a inhibitor
US6680172B1 (en) Treatments and markers for cancers of the central nervous system
EP3133400B1 (en) Use of ak6 and gpx5 male fertility related proteins or combination thereof
JP2012050371A (ja) 免疫抑制物質のスクリーニング方法、免疫抑制活性検出キット及び免疫抑制活性検出マーカー
US9638699B2 (en) Biomarkers of oxidative stress
WO2026052672A1 (en) Comp cleavage peptide and its use in diagnosis of osteoarthritis
KR101849685B1 (ko) 샤르코-마리-투스병 제1형의 원인 유전자로서 ｐｍｐ２２ 및 이를 이용한 상기 질병의 진단방법
WO2008150964A1 (en) Methods and kits for diagnosing and treating acute joint injury
WO2010055525A1 (en) Method for predicting a patient's responsiveness to anti-folate therapy
US20140134627A1 (en) Method for the diagnosis of osteochondrosis
KR20190021678A (ko) 비만 저항성 진단용 조성물
AU2011239262A1 (en) Osteoarthritis biomarkers and uses thereof
WO2003001906A1 (fr) Procede de construction d'un modele animal de maladie des articulations

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted